Ergoteles’s X4 Pharmaceuticals XFOR Stock Holding History

Ergoteles’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,298	Closed	-$365K	–	1642
2021 Q3	$365K	Sell	2,298 -29	-1%	-$4.77K	0.01%	716
2021 Q2	$454K	Buy	+2,327	New	+$585K	0.01%	859

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Ergoteles's XFOR Position: Q4 2021 in Review

Ergoteles sold out of X4 Pharmaceuticals (XFOR) in Q4 2021, closing a stake of 2,298 shares — an estimated $365K sold.

Ergoteles first reported a position in XFOR in Q2 2021 and held it in 2 quarters. The position peaked at $454K in Q2 2021. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2021.

Ergoteles reported no remaining X4 Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 2,298 X4 Pharmaceuticals shares in Q4 2021, an estimated $365K.
Ergoteles first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 2 quarters.
Ergoteles's X4 Pharmaceuticals position peaked at $454K in Q2 2021.
52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.